Top Banner
Detecting an interaction between treatment and a continuous covariate: a comparison between two approaches Willi Sauerbrei Institut of Medical Biometry and Informatics University Medical Center Freiburg, Germany Patrick Royston MRC Clinical Trials Unit, London, UK
21

Patrick Royston MRC Clinical Trials Unit, London, UK

Jan 16, 2016

Download

Documents

SHEPRY

Willi Sauerbrei Institut of Medical Biometry and Informatics University Medical Center Freiburg, Germany. Patrick Royston MRC Clinical Trials Unit, London, UK. Detecting an interaction between treatment and a continuous covariate: a comparison between two approaches. Overview. - PowerPoint PPT Presentation
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Patrick Royston MRC Clinical Trials Unit,  London, UK

Detecting an interaction between treatment and a continuous covariate:

a comparison between two approaches

Willi SauerbreiInstitut of Medical Biometry and Informatics University Medical Center Freiburg, Germany

Patrick RoystonMRC Clinical Trials Unit,

London, UK

Page 2: Patrick Royston MRC Clinical Trials Unit,  London, UK

Overview

Continuous predictive factorsSTEPPMFPI

Example Stability Conclusions

2

Page 3: Patrick Royston MRC Clinical Trials Unit,  London, UK

Detecting predictive factors

Most popular approach- Treatment effect in separate subgroups- Has several problems (Assman et al 2000)

Test of treatment/covariate interaction required - For `binary`covariate standard test for

interaction available Continuous covariate

- Often categorized into two groups3

Page 4: Patrick Royston MRC Clinical Trials Unit,  London, UK

Categorizing a continuous covariate

How many cutpoints? Position of the cutpoint(s) Loss of information loss of power

4

Page 5: Patrick Royston MRC Clinical Trials Unit,  London, UK

New approaches for continuous covariates

STEPPSubpopulation treatment effect pattern plotsBonetti & Gelber 2000

MFPIMultivariable fractional polynomialinteraction approach Royston & Sauerbrei 2004

5

Page 6: Patrick Royston MRC Clinical Trials Unit,  London, UK

STEPP

Sequences of overlapping subpopulations

Sliding window Tail oriented

6

Page 7: Patrick Royston MRC Clinical Trials Unit,  London, UK

STEPP

θ1,...,θk treatment effect in subpopulation P1,...,Pk

7

ˆ ˆ

Estimates in subpopulations

Page 8: Patrick Royston MRC Clinical Trials Unit,  London, UK

STEPP

Overlapping populations, therefore correlation between θ1,...,θk

Simultaneous confidence band and tests proposed

8

ˆ ˆ

Page 9: Patrick Royston MRC Clinical Trials Unit,  London, UK

Fractional polynomial models

9

Fractional polynomial of degree 2 with powers p = (p1,p2) is defined as

FP2 = β1 X p1 + β2 X p2

Powers p are taken from a predefined set S = {2, 1, 0.5, 0, 0.5, 1, 2, 3}

Page 10: Patrick Royston MRC Clinical Trials Unit,  London, UK

Some examples of fractional polynomial curves

(-2, 1) (-2, 2)

(-2, -2) (-2, -1)

10

Page 11: Patrick Royston MRC Clinical Trials Unit,  London, UK

MFPI Have one continuous factor X of interest Use other prognostic factors to build an adjustment

model, e.g. by MFP MFP – combine backward elimination with search

for best FP function Find best FP2 transformation of X with same

powers in each treatment group LRT of equality of reg coefficients Test against main effects model(no interaction)

based on 2 with 2df Distinguish

predefined hypothesis - hypothesis searching11

Page 12: Patrick Royston MRC Clinical Trials Unit,  London, UK

12

RCT: Metastatic renal carcinoma

At risk 1: 175 55 22 11 3 2 1

At risk 2: 172 73 36 20 8 5 1

0.0

00.2

50.5

00.7

51.0

0P

rop

ort

ion

aliv

e

0 12 24 36 48 60 72Follow-up (months)

(1) MPA(2) Interferon

Comparison of MPA with interferon N = 347, 322 Death

Page 13: Patrick Royston MRC Clinical Trials Unit,  London, UK

Overall: Interferon is better (p<0.01)

Is the treatment effect similar in all patients?Sensible questions?- Yes, from our point of view

Ten factors available for the investigation of treatment – covariate interactions

13

Page 14: Patrick Royston MRC Clinical Trials Unit,  London, UK

MFPI Treatment effect function for WCC

Only a result of complex (mis-)modelling?14

-4-2

02

Tre

atm

ent effect, log r

ela

tive h

azard

5 10 15 20White cell count

Original data

Page 15: Patrick Royston MRC Clinical Trials Unit,  London, UK

MFPIStability investigation of the

treatment effect function for WCC100 bootstrap replications of the MFPI procedureIn each replication:1.Step: Select adjustment model2.Step: Estimate treatment effect function

15

-4-2

02

4

Tre

atm

ent effect, log r

ela

tive h

azard

5 10 15 20White cell count

Random sample of 20 curves

Page 16: Patrick Royston MRC Clinical Trials Unit,  London, UK

16

Does the MFPI model agree with the data?

Check proposed trend0

.00

0.2

50

.50

0.7

51

.00

Pro

port

ion a

live

0 12 24 36 48 60 72

Group I

0.0

00

.25

0.5

00

.75

1.0

0

0 12 24 36 48 60 72

Group II

0.0

00

.25

0.5

00

.75

1.0

0P

roport

ion a

live

0 12 24 36 48 60 72Follow-up (months)

Group III

0.0

00

.25

0.5

00

.75

1.0

0

0 12 24 36 48 60 72Follow-up (months)

Group IV

Treatment effect in subgroups defined by WCC

HR (Interferon to MPA; adjusted values similar) overall: 0.75 (0.60 – 0.93)I : 0.53 (0.34 – 0.83) II : 0.69 (0.44 – 1.07)III : 0.89 (0.57 – 1.37) IV : 1.32 (0.85 –2.05)

Page 17: Patrick Royston MRC Clinical Trials Unit,  London, UK

STEPP – Interaction with WCC

17

SLIDING WINDOW (n1 = 25, n2 = 40)

TAIL ORIENTED (g = 8)

Page 18: Patrick Royston MRC Clinical Trials Unit,  London, UK

STEPP as check of MFPI

18

Page 19: Patrick Royston MRC Clinical Trials Unit,  London, UK

MFPI – Type I error Random permutation of a continuous covariate (haemoglobin) no interaction

Distribution of P-value from test of interaction1000 runs, Type I error: 0.054

19

0.5

11.

5D

ensi

ty

0 .2 .4 .6 .8 1p

Page 20: Patrick Royston MRC Clinical Trials Unit,  London, UK

Conclusions Cutpoints approaches have several problems More power by using all information from continuous

factors STEPP and MFPI may detect important predictive

effects which may be missed by standard methodology STEPP: step in the right direction, still depends on

cutpoints and is more unstable MFPI: no cutpoints required, estimates continuous

treatment effect function, promising results from stability and type I error investigations

Important differentiation: prespecified hypothesis or hypothesis generation (interpretation, multiple testing)

20

Page 21: Patrick Royston MRC Clinical Trials Unit,  London, UK

21

ReferencesAssman SF, Pocock S, Enos LE, Kasten LE (2000): Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet, 355, 1064-1069.

Bonetti M, Gelber RD (2000): A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data. Statistics in Medicine, 19, 2595-2609.

Bonetti M, Gelber RD (2004): Patterns of treatment effects in subsets of patients in clinical trials. Biostatistics, 5,465-481.

Royston P, Sauerbrei W (2004): A new approach to modelling interactions between treatment and covariates in clinical trials by using fractional polynomials. Statistics in Medicine, 23, 2509-2525.

Royston P, Sauerbrei W, Ritchie A (2004): Is treatment with interferon-a effective in all patients with metastatic renal carcinoma? A new approach to the investigation of interactions. British Journal of Cancer, 90, 794-799.

Sauerbrei W, Royston P (1999): Building multivariable prognostic and diagnostic models: transformation of the predictors by using fractional polynomials. Journal of the Royal Statistical Society A, 162, 71-94.

Sauerbrei W, Royston P, Zapien K (2006): Detecting an interaction between treatment and a continuous covariate: a comparison between two approaches, submitted.